SAS Output

26-MAY-2017 18:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1320-Adv, BRAF mut, Inter v Contin 1 Y 1 Lead-in Continuous Dosing 280 152 57 29 18 5 5 09/19/2014 242 100
            152 57 29 18 5 5      
 
    2 Y 2 Continuous Dosing 280 59 18 10 6 2 2 09/19/2014    
        3 Intermittent Dosing   61 21 13 6 0 0      
            120 39 23 12 2 2      
 
  S1404-Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 1 Y 1 Tissue for PD-L1 testing 1378 1150 980 545 279 92 20 11/10/2015 416 174
            1150 980 545 279 92 20      
 
    2 Y 2 FDA approved regimen 1378 525 460 268 130 38 15 11/10/2015    
        3 MK-3475 (Pembrolizumab)   518 454 254 132 39 8      
            1043 914 522 262 77 23      
 
  S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) 1 Y 1 MK-3475 (pembrolizumab) 77 1 1 1 0 0 0 02/06/2017 49 20
            1 1 1 0 0 0      
 
Yes EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 1 E Total Registrations   16 12 5 3 1 0 11/03/2015 340 137
            16 12 5 3 1 0      
 
    2 E Total Registrations   3 3 1 0 0 0 11/03/2015    
            3 3 1 0 0 0      
 
  EA6141-Melan, Avd, Nivolumab+Ipi ± Sargmostim 1 E Total Registrations   30 28 17 12 8 1 03/25/2016 263 102
            30 28 17 12 8 1      
 
No E3612-MELAN,Adv Ipilimumab±Bevacizumab 1 E Total Registrations   5 1 0 0 0 0 02/16/2015 146 56
            5 1 0 0 0 0